Literature DB >> 26503205

Targeting Programmed Cell Death 1 in Ovarian Cancer.

Krisztian Homicsko1, George Coukos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26503205     DOI： 10.1200/JCO.2015.63.7785

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Authors:  Anne Montfort; Oliver Pearce; Eleni Maniati; Benjamin G Vincent; Lisa Bixby; Steffen Böhm; Thomas Dowe; Edmund H Wilkes; Probir Chakravarty; Richard Thompson; Joanne Topping; Pedro R Cutillas; Michelle Lockley; Jonathan S Serody; Melania Capasso; Frances R Balkwill
Journal:  Clin Cancer Res       Date:  2016-06-27       Impact factor: 12.531

2.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

Authors:  Junzo Hamanishi; Nobuhiro Takeshima; Noriyuki Katsumata; Kimio Ushijima; Tadashi Kimura; Satoshi Takeuchi; Koji Matsumoto; Kimihiko Ito; Masaki Mandai; Hidekatsu Nakai; Noriaki Sakuragi; Hidemichi Watari; Nobutaka Takahashi; Hidenori Kato; Kosei Hasegawa; Kan Yonemori; Mika Mizuno; Kazuhiro Takehara; Hitoshi Niikura; Takashi Sawasaki; Sari Nakao; Toshiaki Saito; Takayuki Enomoto; Satoru Nagase; Nao Suzuki; Takashi Matsumoto; Eiji Kondo; Kenzo Sonoda; Satomi Aihara; Yoichi Aoki; Aikou Okamoto; Hirokuni Takano; Hiroshi Kobayashi; Hisamori Kato; Yoshito Terai; Akira Takazawa; Yusuke Takahashi; Yoshinobu Namba; Daisuke Aoki; Keiichi Fujiwara; Toru Sugiyama; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2021-09-02       Impact factor: 44.544

4.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.

Authors:  Chunbai He; Xiaopin Duan; Nining Guo; Christina Chan; Christopher Poon; Ralph R Weichselbaum; Wenbin Lin
Journal:  Nat Commun       Date:  2016-08-17       Impact factor: 14.919

5.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

Authors:  Alejandro Jiménez-Sánchez; Danish Memon; Stephane Pourpe; Harini Veeraraghavan; Yanyun Li; Hebert Alberto Vargas; Michael B Gill; Kay J Park; Oliver Zivanovic; Jason Konner; Jacob Ricca; Dmitriy Zamarin; Tyler Walther; Carol Aghajanian; Jedd D Wolchok; Evis Sala; Taha Merghoub; Alexandra Snyder; Martin L Miller
Journal:  Cell       Date:  2017-08-24       Impact factor: 41.582

6.  A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Authors:  B J Monk; M F Brady; C Aghajanian; H A Lankes; T Rizack; J Leach; J M Fowler; R Higgins; P Hanjani; M Morgan; R Edwards; W Bradley; T Kolevska; P Foukas; E M Swisher; K S Anderson; R Gottardo; J K Bryan; M Newkirk; K L Manjarrez; R S Mannel; R M Hershberg; G Coukos
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

7.  Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.

Authors:  Mengjiao Li; Haoran Li; Fei Liu; Rui Bi; Xiaoyu Tu; Lihua Chen; Shuang Ye; Xi Cheng
Journal:  J Ovarian Res       Date:  2017-02-10       Impact factor: 4.234

8.  Comprehensive discovery of subsample gene expression components by information explanation: therapeutic implications in cancer.

Authors:  Shirley Pepke; Greg Ver Steeg
Journal:  BMC Med Genomics       Date:  2017-03-15       Impact factor: 3.063

9.  Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.

Authors:  Jun Zhu; Hao Wen; Rui Bi; Yong Wu; Xiaohua Wu
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401

10.  VISTA expressed in tumour cells regulates T cell function.

Authors:  Kumuluzi Mulati; Junzo Hamanishi; Noriomi Matsumura; Kenji Chamoto; Nathan Mise; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Naoki Horikawa; Ryusuke Murakami; Mana Taki; Kharma Budiman; Xiang Zeng; Yuko Hosoe; Miyuki Azuma; Ikuo Konishi; Masaki Mandai
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.